Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience.

An G, Jin J, Cai Z, Jing H, Fu C, He P, Xia Z, Xu Q, Liu R, Li L, Gai X, Zhang H, Zhu D, Luo X, Campagna M, Masterson TJ, Lau BW, Renaud T, Heuck C, Qiu L

Open source

DOI: 10.1080/16078454.2026.2702681
Published: 2026 Dec 31
Container: Hematology (Amsterdam, Netherlands)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/16078454.2026.2702681,
  title = {Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience.},
  author = {An G and Jin J and Cai Z and Jing H and Fu C and He P and Xia Z and Xu Q and Liu R and Li L and Gai X and Zhang H and Zhu D and Luo X and Campagna M and Masterson TJ and Lau BW and Renaud T and Heuck C and Qiu L},
  year = {2026},
  journal = {Hematology (Amsterdam, Netherlands)},
  doi = {10.1080/16078454.2026.2702681},
  url = {https://doi.org/10.1080/16078454.2026.2702681}
}

RIS

TY  - JOUR
TI  - Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience.
AU  - An G
AU  - Jin J
AU  - Cai Z
AU  - Jing H
AU  - Fu C
AU  - He P
AU  - Xia Z
AU  - Xu Q
AU  - Liu R
AU  - Li L
AU  - Gai X
AU  - Zhang H
AU  - Zhu D
AU  - Luo X
AU  - Campagna M
AU  - Masterson TJ
AU  - Lau BW
AU  - Renaud T
AU  - Heuck C
AU  - Qiu L
PY  - 2026
JO  - Hematology (Amsterdam, Netherlands)
DO  - 10.1080/16078454.2026.2702681
UR  - https://doi.org/10.1080/16078454.2026.2702681
ER  -

APA

G, A., J, J., Z, C., H, J., C, F., P, H., Z, X., Q, X., R, L., L, L., X, G., H, Z., D, Z., X, L., M, C., TJ, M., BW, L., T, R., C, H., & L, Q. (2026). Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience.. Hematology (Amsterdam, Netherlands). https://doi.org/10.1080/16078454.2026.2702681

Source records

pubmed · retrieved 2026-09-26T18:55:20.621Z